TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:59
AVENUE THERAPEUTICS INC. ( ATXI ) https://www.avenuetx.com
1.86USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-84.93%
ATXI
SPY
32.66%
-99.83%
ATXI
SPY
108.59%
-99.98%
ATXI
SPY
302.52%
ATXI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2.98
0.38
0.02
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.31
0.00
1.80
-861.68
0.00
-0.04
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
2.3696
-1411.29
-655.26
-0.53
Other Earnings and Cash Flow Stats:
AVENUE THERAPEUTICS INC. ( ATXI ) Net Income TTM ($MM) is -9.47
AVENUE THERAPEUTICS INC. ( ATXI ) Operating Income TTM ($MM) is -11.81
AVENUE THERAPEUTICS INC. ( ATXI ) Owners' Earnings Annual ($MM) is 0.00
AVENUE THERAPEUTICS INC. ( ATXI ) Current Price to Owners' Earnings ratio is 0.00
AVENUE THERAPEUTICS INC. ( ATXI ) EBITDA TTM ($MM) is -5.79
AVENUE THERAPEUTICS INC. ( ATXI ) EBITDA Margin is 0.00%
Capital Allocation:
AVENUE THERAPEUTICS INC. ( ATXI ) has paid 0.00 dividends per share and bought back 6.513966 million shares in the past 12 months
AVENUE THERAPEUTICS INC. ( ATXI ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
AVENUE THERAPEUTICS INC. ( ATXI ) Interest-bearing Debt ($MM) as of last quarter is 0
AVENUE THERAPEUTICS INC. ( ATXI ) Annual Working Capital Investments ($MM) are 0
AVENUE THERAPEUTICS INC. ( ATXI ) Book Value ($MM) as of last quarter is 1
AVENUE THERAPEUTICS INC. ( ATXI ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
AVENUE THERAPEUTICS INC. ( ATXI ) has 2 million in cash on hand as of last quarter
AVENUE THERAPEUTICS INC. ( ATXI ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
AVENUE THERAPEUTICS INC. ( ATXI ) has 1 common shares outstanding as of last quarter
AVENUE THERAPEUTICS INC. ( ATXI ) has 0 million USD of preferred stock value
Academic Scores:
AVENUE THERAPEUTICS INC. ( ATXI ) Altman Z-Score is -67.44 as of last quarter
AVENUE THERAPEUTICS INC. ( ATXI ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
AVENUE THERAPEUTICS INC. ( ATXI ) largest shareholder is owning shares at 0.00 ($MM) value
Herskowitz Neil(an insider) Sold 23 shares of AVENUE THERAPEUTICS INC. ( ATXI ) for the amount of $46.00 on 2024-12-02
9.85% of AVENUE THERAPEUTICS INC. ( ATXI ) is held by insiders, and 10.33% is held by institutions
AVENUE THERAPEUTICS INC. ( ATXI ) went public on 2017-06-27
Other AVENUE THERAPEUTICS INC. ( ATXI ) financial metrics:
FCF:-16.59
Unlevered Free Cash Flow:0.00
EPS:-7.69
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-471.42
Beta:-0.53
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AVENUE THERAPEUTICS INC. ( ATXI ) :
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.